Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke

Acute ischemic stroke is a leading cause of death in the US and in need of safer, more effective treatment options. Learn more about the stroke therapeutic landscape in the Drug Discovery Online guest column “Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke” written by Basking co-founder and CMO Shahid Nimjee. He discusses the limitations of current treatments for acute ischemic #stroke, applicability of RNA aptamers as drug candidates and Basking’s lead candidate BB-031, a novel aptamer targeting vWF. https://lnkd.in/gtErnYNq